deltatrials
Active Not Recruiting NA INTERVENTIONAL 5-arm NCT02352883

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Ductal Breast Carcinoma In Situ
Interventions Cytology Specimen Collection Procedure Endocrine Therapy Laboratory Biomarker Analysis Magnetic Resonance Imaging Quality-of-Life Assessment Radiation Therapy Therapeutic Conventional Surgery Therapeutic Surgical Procedure
Updated 14 times since 2017 Last updated: Dec 17, 2025 Started: Mar 25, 2015 Primary completion: Nov 30, 2027 Completion: Nov 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Ductal Breast Carcinoma In Situ, this trial is ongoing. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Nov 2020 · 15 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2022 · 18 months · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 5 months · monthly snapshot

Change History

14 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting NA

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting NA

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting NA

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting NA

  5. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting NA

▶ Show 9 earlier versions

  1. Jul 2023 — Jul 2024 [monthly]

    Active Not Recruiting NA

  2. Jul 2022 — Jul 2023 [monthly]

    Active Not Recruiting NA

  3. Jan 2021 — Jul 2022 [monthly]

    Active Not Recruiting NA

  4. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting NA

  5. Aug 2019 — Nov 2020 [monthly]

    Active Not Recruiting NA

  6. Jun 2018 — Aug 2019 [monthly]

    Active Not Recruiting NA

  7. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting NA

    Status: Recruiting → Active Not Recruiting

  8. Feb 2017 — Nov 2017 [monthly]

    Recruiting NA

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ECOG-ACRIN Cancer Research Group
  • Eastern Cooperative Oncology Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States , Atlantis, United States , Avon, United States , Baton Rouge, United States , Bryn Mawr, United States , Canton, United States , Chicago, United States , Cincinnati, United States , Dallas, United States , Dodge City, United States and 48 more locations